Latest / CME Outfitters Medical Education / CME Snack FGF21 Frontier in Clinically Significant MASH
Transcript
- 0:01SPEAKER_00: Today's activity may include discussion of products or devices that are not currently labeled for use by the US FDA.
- 0:10SPEAKER_00: Hello and welcome.
- 0:12SPEAKER_00: I'm Dr.
- 0:12SPEAKER_00: Chris Cowdlee.
- 0:14SPEAKER_00: On behalf of CME Outfitters, I would like to welcome and thank you for joining us for the CMEO SNAC titled The FGF 21 Frontier in Clinically Significant MASH.
- 0:26SPEAKER_00: This activity is supported by an educational grant from Nova Nordisk.
- 0:31SPEAKER_00: Here are our learning objectives.
- 0:33SPEAKER_00: After participating in this activity, learners should be better able to one evaluate the biology of FGF-21 within metabolic and fibrotic pathways, two, assess emerging clinical evidence for FGF-21 analogs in clinically significant MASH.
- 0:54SPEAKER_00: And three, appraise the rationale for FGF-21 pathway therapy in compensated cirrhosis due to MASH.
- 1:04SPEAKER_00: Again, I'm Dr.
- 1:05SPEAKER_00: Chris Cowdlee.
- 1:06SPEAKER_00: I'm a professor at the Elson S.
- 1:08SPEAKER_00: Floyd College of Medicine at Washington State University, director at Liver Institute Northwest, and medical director and senior scientific advisor at Velocity Clinical Research.
- 1:19SPEAKER_00: And I'm very pleased to be joined today by my colleague, Dr.
- 1:23SPEAKER_00: Maru Renella, who I will ask to introduce herself.
- 1:27SPEAKER_00: Maru.
- 1:29SPEAKER_01: Great.
- 1:29SPEAKER_01: Thank you very much, Chris.
- 1:30SPEAKER_01: And I'm really excited to participate in this event.
- 1:33SPEAKER_01: I'm Maru Renella, Professor of Medicine at the University of Chicago.
- 1:37SPEAKER_01: I am director of clinical trials in the section of gastroneurology, and I'm also the director of the metabolic liver program.
- 1:46SPEAKER_00: Thanks, Maru.
- 1:48SPEAKER_00: Really looking forward to our discussion today.
- 1:49SPEAKER_00: So let me start by addressing where the unmet need sits in MASH.
- 1:56SPEAKER_00: So we know that in MASH, as fibrosis progresses, there is a direct relationship between advancing fibrosis and mortality, both liver-related mortality, and as patients progress to more advanced fibrosis, all cause mortality.
- 2:14SPEAKER_00: And you can see that 0.3 deaths per year per 100 person years is reported for F0, F2 patients, which then increases to 0.9, and in F4 patients, 1.8 deaths per 100 person years.
- 2:30SPEAKER_00: Now in non-serotic MASH, that is in patients who have F2, F3 fibrosis, we have FDA-approved therapies, and these include RISMeter ROM and semaglitide injections.
- 2:44SPEAKER_00: RISMeterom is an oral therapy, and both indications are approved under the FDA accelerated pathway.
- 2:53SPEAKER_00: However, for patients who have cirrhosis, whether it's compensated and certainly decompensated, there are no FDA-approved pharmacotherapies for mass-related compensated cirrhosis.
- 3:08SPEAKER_00: Now, as I've already mentioned, this is really important because in patients who have cirrhosis, there's an increase in all-cause mortality and not just liver-related mortality.
- 3:19SPEAKER_00: And the increase is dramatically increased.
- 3:22SPEAKER_00: So we're talking about a 2.4 to 2.5-fold increased mortality in patients who have F2 fibrosis that now increases to 30 to 40-fold in patients who have cirrhosis.
- 3:35SPEAKER_00: So this population represents a key unmet need and a population that is really in urgent need for therapies to slow down the progression of disease and hopefully reverse cirrhosis.
- 3:50SPEAKER_00: So before we continue, let's get our audience involved.
- 3:54SPEAKER_00: Which statement best describes the biology of FGF-21 relevant to its investigation as a therapeutic target in MASH?
- 4:03SPEAKER_00: A FGF-21 acts primarily in the liver to reduce hepatic inflammation and directly limit fibrotic activity.
- 4:12SPEAKER_00: B FGF 21 signals through FGFR1C beta clotho to coordinate metabolic effects across the liver, adipose tissue, and other tissues.
- 4:24SPEAKER_00: C FGF-21 acts primarily in the intestine to reduce lipid absorption and thereby decrease hepatic fat accumulation.
- 4:32SPEAKER_00: D.
- 4:33SPEAKER_00: FGF 21 signals primarily through hepatic inflammatory pathways to reduce liver injury without substantial systemic metabolic effects.
- 4:42SPEAKER_00: And E.
- 4:43SPEAKER_00: I don't know.
- 4:45SPEAKER_00: So let's pause for a few seconds.
- 5:03SPEAKER_00: The correct answer is B.
- 5:05SPEAKER_00: So let's uh talk about FGF 21 and how FGF 21 might play a role that is highly desirable and attractive in treating patients who have cirrhosis related to MASH.
- 5:18SPEAKER_00: So FGF-21 is a stress-responsive endocrine hormone and FGFR1C and beta clotho signal through C isoform FGF receptors, predominantly FGFR1C, with beta clotho as an obligate co-receptor.
- 5:36SPEAKER_00: And this allows tissue-specific signaling and the distribution of beta-clotho really helps define where FGF-21 can act and achieve the greatest metabolic effects.
- 5:49SPEAKER_00: And that incorporates or includes the liver, adipose tissue, the pancreas, and the central nervous system.
- 5:57SPEAKER_00: So the take-home message here is FGF-21 is a multi-system endocrine regulator.
- 6:04SPEAKER_00: Its therapeutic rationale and mash reflects a coordinated metabolic and possibly more importantly, or as importantly, fibrotic pathway effects.
- 6:17SPEAKER_00: And FGF 21 analogs have pleotropic effects that are really attractive from the standpoint of what we hope to achieve in treating patients who have cirrhosis related to MASH.
- 6:31SPEAKER_00: Now, why FGF-21 analogs rather than native FGF-21?
- 6:38SPEAKER_00: And here it's important to keep in mind that if you look at the FGF-21 analogs, they come in many different forms.
- 6:46SPEAKER_00: And because of the way they're constructed, dosing can be quite variable with these different forms.
- 6:54SPEAKER_00: So you can have fatty diacid conjugation, you can achieve pegylation, and many of us are familiar with pegylation being able to provide longer-acting results, or FC fusion.
- 7:07SPEAKER_00: So if you look at fatty diacid conjugation, xalfermin was a compound that is currently not being developed, as was pegalfermin, but pegasofermin is currently in clinical development, as is effruxofermin and ephemusfermin.
- 7:23SPEAKER_00: And because of the way these conjugates have been developed, we can see that dosing can be quite variable and may be administered weekly, once a month, or weekly or every two weeks.
- 7:40SPEAKER_00: Now it's important to keep in mind how do we interpret this burgeoning and emerging evidence with FGF-21.
- 7:48SPEAKER_00: So, Maru, can you please talk us through the FGF-21 agents in development and how to interpret what is an accumulating amount of data with regard to these compounds?
- 7:59SPEAKER_01: Yeah, thank you.
- 8:00SPEAKER_01: So, yeah, this is a really exciting uh class of compounds.
- 8:04SPEAKER_01: Um, and it's important, I think, just to set out and make it quite clear that these are still in investigational uh state.
- 8:13SPEAKER_01: The current evidence that we have, and efficacy evidence specifically, is derived from phase two and phase two B trials.
- 8:22SPEAKER_01: Phase three trials are not yet complete, but they are well underway and ongoing, and hopefully we'll have results in the next couple of years.
- 8:32SPEAKER_01: It's important as we go through some of these trials that we do not compare drugs side to side.
- 8:41SPEAKER_01: Why is this important?
- 8:42SPEAKER_01: It's important because the design of these studies is different, the populations are a bit different, the endpoints and the time points at which these endpoints are done are also different.
- 8:55SPEAKER_01: And then within a given study, there are different analysis sets, and the studies also have different follow-up durations.
- 9:03SPEAKER_01: So that's why it's important to not take one value and compare it from one trial to the next.
- 9:09SPEAKER_01: And again, the timing of when these endpoints are derived is also really important.
- 9:14SPEAKER_01: So, for example, if you have a study that has a primary endpoint at 24 weeks versus 96 weeks, you might imagine that it would take uh, you know, in some cases, more time, right, for fibrosis to improve.
- 9:27SPEAKER_01: And so you can't really compare an endpoint that's earlier with a later endpoint.
- 9:31SPEAKER_01: And that's important to keep in mind because they have different uh timings for these uh endpoints.
- 9:38SPEAKER_01: Um so I guess let's move on to the first uh study that we're gonna cover, and this is uh the enlivened trial.
- 9:45SPEAKER_01: This is on Pagosa Fermin, and it's a histologic outcome study.
- 9:50SPEAKER_01: The primary endpoint was set at 24 weeks.
- 9:53SPEAKER_01: And this study was entirely for uh targeting stage two and stage three patients with MASH.
- 10:01SPEAKER_01: This study was a had a co-primary endpoint, and these two endpoints that you see on the slide are the two regulatory endpoints that are accepted by FDA for conditional or accelerated approval.
- 10:15SPEAKER_01: On your left, you can see the co-primary endpoint of greater than or equal to one stage of fibrosis improvement without worsening of MASH.
- 10:23SPEAKER_01: You can see that this analysis is based on the full analysis population.
- 10:29SPEAKER_01: And you can note that in placebo, which had 7% of patients achieving this endpoint, there was an increase in a dose-dependent manner across the 15 and 30 milligram groups, which were weekly dosing, and then the 14, the uh sorry, 44 milligram dose was in every other week dosing.
- 10:50SPEAKER_01: But you can see that there was statistical significance across these treatment groups in the 30 milligram and in the 44 milligram group.
- 10:58SPEAKER_01: Looking at mash resolution, there were notable differences between uh achieving mass resolution in the treatment groups versus the placebo, but the uh dose response is not clear.
- 11:12SPEAKER_01: The numbers are very small, but in general, you can see there was a significant meaning not statistically specifically, because this is a nominal uh P-value, but you can see that there is a difference between placebo and treatment on the order of 20 percentage points or so.
- 11:31SPEAKER_01: Safety is an important thing to notice with any drug and in this particular class of drugs and in many in this disease space, the most common adverse events are GI-related, specifically nausea and diarrhea, as well as injection site uh erythema.
- 11:49SPEAKER_01: And these occurred numerically more in the Pagosa Furman study in a dose-dependent manner.
- 11:55SPEAKER_01: And then interestingly, in the uh in the 44 milligram dosing group, which was every other week, a little bit lower uh incidence of the SAEs, uh, with the exception of one uh uh evident um pancreatitis, which is attributed uh to the drug.
- 12:12SPEAKER_01: So moving on to ephemisfermin alpha.
- 12:15SPEAKER_01: So the pegosfermin is a pegylated form of FGF-21 analog.
- 12:20SPEAKER_01: Ephemisfermin is is uh a different way of modifying uh the compound, and this is an FC fusion protein.
- 12:28SPEAKER_01: This trial is also a phase two trial in stage two to three uh MASH.
- 12:34SPEAKER_01: Again, a small study, 84 patients.
- 12:37SPEAKER_01: Primary endpoint here was safety and tolerability, but um we're showing you here the exploratory histologic outcomes that were obtained also at 24 weeks.
- 12:48SPEAKER_01: So here there was only one dose uh uh that is uh being compared here, 300 milligrams to placebo.
- 12:56SPEAKER_01: And this is after 24 weeks, there were statistical significance in the comparison of the placebo versus uh treatment group.
- 13:04SPEAKER_01: And I however it's important to note this is a biopsy analysis uh set.
- 13:09SPEAKER_01: Um in in this particular trial, the end point was at 24 weeks, but there was a 24-week uh open label extension, meaning that the two uh dosing groups um were extended out, and I mean so the two group, the groups would extend it out and place, including placebo, which was converted over to drug.
- 13:28SPEAKER_01: And you can see here that there's a sustained uh response in at the 48-week point, which is an important thing to demonstrate in this class of compounds, in any class of drugs, but really in this one it's very important because with um prior uh studies with um Peg Belfermin, for example, this was unable to sustain response over time.
- 13:52SPEAKER_01: So this is really important uh that this demonstrated at least sustained response at 48 weeks.
- 13:58SPEAKER_01: And then the second exploratory histological outcome, which was mass resolution without worsening a fibrosis, you can see also uh very nice separation between drug treatment and placebo.
- 14:11SPEAKER_01: Um, and then again, this was sustained at 48 weeks.
- 14:14SPEAKER_01: So, again, this was um a small study, but certainly very favorable results, inconsistent with what we've seen in other FGF-21 analogs.
- 14:23SPEAKER_01: Um, the safety uh data here is very similar, um, mild to moderate uh in in intensity as far as severity of uh AEs, and they were GI related uh as well.
- 14:37SPEAKER_01: Two specific SAE occurred in the ephemus fermin group, and one of these was determined to be treatment related.
- 14:44SPEAKER_01: So fairly similar tolerability profiles.
- 14:48SPEAKER_00: Well, thanks for a great summary, Maru.
- 14:50SPEAKER_00: So before we continue, here's our second audience response question.
- 14:54SPEAKER_00: Across the phase two and two B trials of FGF21 analogs and F2F3 MASH, placebo fibrosis improvement rates quite variable, ranging from 7 to 21%.
- 15:07SPEAKER_00: Uh what does that variability most directly affect?
- 15:12SPEAKER_00: A, the absolute response rate in treated patients, B nothing because the endpoints were pre-specified, C, the apparent size of the treatment effect, the safety profile of the class, that's D.
- 15:27SPEAKER_00: And E, I don't know.
- 15:46SPEAKER_00: And the correct answer is C.
- 15:48SPEAKER_00: Um we'll learn more about that now.
- 15:50SPEAKER_00: Uh, Maru, can you take us through Harmony?
- 15:53SPEAKER_01: Yes, absolutely.
- 15:55SPEAKER_01: So this is um the third FGF-21 analog that we're going to cover today.
- 15:59SPEAKER_01: This is a frucermin, and this is also an FC fusion protein uh molecule.
- 16:05SPEAKER_01: And this particular study was the histological outcome study carried out through 96 weeks in patients with stage two to three MASH.
- 16:14SPEAKER_01: Um, so just I guess walking you through to start, the primary endpoint of this trial was a greater than or equal to one stage fibrosis improvement without worsening of MASH.
- 16:26SPEAKER_01: Here you can see the data presented in two different ways.
- 16:31SPEAKER_01: So on the left, you can see the modified intention to treat population, and on the right, you can see the biopsy analysis set.
- 16:39SPEAKER_01: So starting with the modified ITT population, you can see that at the 24-week mark, there were uh differences between the treatment groups, which were 28 milligrams and 50 milligrams compared to placebo.
- 16:54SPEAKER_01: Um, these did not, the 50 milligram group did not meet statistical significance at this at this 24-week time point on ITT.
- 17:03SPEAKER_01: When you look at the liver biopsy analysis set, this was now uh statistically significant in both the 28 and the 50 milligram groups.
- 17:12SPEAKER_01: Now extending out to 96 weeks, so again, more uh treatment uh drug exposure over time.
- 17:19SPEAKER_01: So what we're looking for here is any augmentation of efficacy and certainly sustaining of efficacy, those are important things to show.
- 17:28SPEAKER_01: So what you can see in the intention to treat population is a very nice and more decisive separation between the 50 milligram group specifically and placebo, uh, both and which reach reach statistical significance.
- 17:44SPEAKER_01: Um, in the 28 milligram group, this was not statistically significant.
- 17:49SPEAKER_01: If you look to the uh liver biopsy analysis set, the results are are very similar.
- 17:54SPEAKER_01: Uh, of course, the the differences are going to be greater because these are patients who had a full uh biopsies uh on both ends to actually analyze.
- 18:04SPEAKER_01: But remarkably, at 96 weeks, uh 75% of the patients in the 50 milligram group uh have now achieved a greater than or equal to one-stage improvement in fibrosis compared to 24% in placebo.
- 18:17SPEAKER_01: And while there wasn't a statistical significant difference on in the 28 milligram group compared to placebo, you can see really nice dose-dependent increases, which gives you uh you know confidence in a little bit more confidence in the results.
- 18:33SPEAKER_01: So, with respect to safety, uh this uh particular compound, again, similar to the others, uh GA GI adverse events were the most common.
- 18:43SPEAKER_01: Um, and this was more uh in froxifirmic compared to placebo.
- 18:47SPEAKER_01: Uh the SAEs occurred in 10, 16, and 9% uh of the of the groups, and that is the 9% is in the placebo, so um incremental uh uh worse or more SAEs in the uh higher dose and then less in placebo uh respectively.
- 19:10SPEAKER_00: Yeah, thank you.
- 19:11SPEAKER_00: It's it's always reassuring to me when I see a dose response effect uh that it's a proof of mechanism in addition to proof of efficacy.
- 19:22SPEAKER_00: Um is that your take as well?
- 19:24SPEAKER_00: And these results, although the numbers are small, etc., uh, are really quite encouraging that we might be able to uh you know reverse this progressive disease.
- 19:34SPEAKER_01: Yeah, no, I think I think these are really exciting results.
- 19:36SPEAKER_01: I think generally the results in all of the drugs in this class are really encouraging.
- 19:41SPEAKER_01: And I think that the biggest uh you know challenge is going to be to see how well we sustain uh the response.
- 19:49SPEAKER_01: And in this particular trial, we're not showing these data here, but uh basically there were um people who responded later, and that's really important.
- 19:59SPEAKER_01: So you have um not just sustained response, but you have late what you would call, I guess you could call late responders or people who continue to respond over time that hadn't responded pre previously.
- 20:10SPEAKER_01: So I think that just tells you what I think we know.
- 20:13SPEAKER_01: This is a chronic disease, and you do need to treat it for a longer period of time than 24 weeks, basically.
- 20:19SPEAKER_00: Yeah, and and we've known this for years with every liver disease that collagen deposition and fibrosis formation is quite quick, but resolution of fibrosis generally takes much longer, maybe uh a log factor longer.
- 20:34SPEAKER_00: So um, so with that's a great uh segue to go into the next population, which is patients with cirrhosis.
- 20:42SPEAKER_00: And um, and this is a much more difficult population, isn't it, um, Maroon?
- 20:48SPEAKER_00: Let me uh talk about why this would be.
- 20:51SPEAKER_00: Uh, you know, first we have to define compensated cirrhosis.
- 20:54SPEAKER_00: I think most of us would agree that decompensated cirrhosis, um, you know, the the horse may be out of the barn, it may be tough to really bring those patients back into recompensation.
- 21:05SPEAKER_00: But certainly in compensated cirrhosis, I think we still have high hopes.
- 21:09SPEAKER_00: But um it becomes challenging because the spectrum of compensated cirrhosis can be quite wide from really compensated to maybe tiptoeing on the edge of portal hypertension.
- 21:21SPEAKER_00: But we would definitely uh agree that patients with uh child Pew a cirrhosis with no history of a decompensating event in the past would be the minimum requirement to define compensated cirrhosis.
- 21:38SPEAKER_00: But this is not a homogeneous population.
- 21:41SPEAKER_00: Um we know what low platelets mean, but we don't know what it means when a patient has a platelet count of 155 versus 145.
- 21:50SPEAKER_00: And the etiologies may be different, and the burden of fibrosis may be different.
- 21:55SPEAKER_00: And then, of course, uh portal hypertension severity definition.
- 22:00SPEAKER_00: An apatic reserve can vary substantially, largely because we're looking at a sort of an ordinal category of patients with cirrhosis, but the burden of fibrosis in an individual patient, even without clinically significant portal hypertension, may be quite variable.
- 22:18SPEAKER_00: And of course, that directly relates to why these are very challenging clinical trials.
- 22:24SPEAKER_00: You have a heterogeneous patient population that makes patient enrollment and enrichment of this population challenging.
- 22:35SPEAKER_00: I think we already alluded to the fact that once you have mature type 1 collagen-established scar, it's very different from removing collagen that may be less established, may remodel more slowly.
- 22:51SPEAKER_00: And endpoint selection is really challenging, right?
- 22:54SPEAKER_00: Because it depends on whether you're talking about fibrosis regression, which may have a regulatory definition, but clinically it's very hard to know what that means.
- 23:07SPEAKER_00: Then you're talking about clinical outcomes, and then we are stuck with the usual debates about listing for transplant versus actually transplanting patients, melt score evolution, a new clinical decompensation event, et cetera.
- 23:22SPEAKER_00: And these studies generally would require much longer follow-up and much uh really uh much more rigorous adjudication uh by adjudication committees.
- 23:35SPEAKER_00: So um the symmetry trial did in fact look at patients with cirrhosis.
- 23:41SPEAKER_00: Uh and uh Maru, can you walk us through that study?
- 23:44SPEAKER_00: Very exciting results.
- 23:46SPEAKER_01: Yeah, no, it is a very exciting study.
- 23:48SPEAKER_01: And I I I you're you summarized it really well why you know cirrhosis is so hard to study.
- 23:53SPEAKER_01: I mean, I would argue actually that the heterogeneity in cirrhosis, uh so in that one stage, is more than the rest of the stages uh together because and and it's very difficult to identify the differences clearly.
- 24:06SPEAKER_01: So that's really made it challenging.
- 24:08SPEAKER_01: The other thing that makes it really challenging to study cirrhosis is that there is no reasonably likely surrogate and endpoint that's accepted by the FDA.
- 24:17SPEAKER_01: So in these trials that we've reviewed that are stage two to three, there the histologic changes that I mentioned you are regulatory endpoints for, you know, for the reasonably likely surrogates that are going to result potentially in um accelerated approval.
- 24:34SPEAKER_01: We don't have that in cirrhosis.
- 24:35SPEAKER_01: So the histology change is something that's being, you know, that's been allowed by the agency, and we hope that it's that they that this will be something that will help uh drugs get approved.
- 24:50SPEAKER_01: We just don't know though for sure what's gonna happen.
- 24:53SPEAKER_01: But in any case, I'm gonna review the results of the symmetry trial, which um in my mind were probably the most exciting results in in uh in in this particular field uh because of the difficulty of treating cirrhosis, I will say.
- 25:08SPEAKER_01: So this uh study was set up with a 36-week primary endpoint, and the primary endpoint uh was histology.
- 25:16SPEAKER_01: So um what we're gonna uh show first is the 36-week histology endpoint.
- 25:22SPEAKER_01: That is a primary endpoint of the trial, and therefore that primary endpoint was not met at 36 weeks.
- 25:28SPEAKER_01: Okay, you can see that there's no statistical significant difference between the 28 milligram, 50 milligram, and placebo group at 36 weeks.
- 25:37SPEAKER_01: Um now, if you extend that to 96 weeks, so now you're allowing for a longer period of time that the that the patients are exposed to the drug, you start to see a very nice separation between drug treatment and placebo.
- 25:54SPEAKER_01: Um these are not you know, they're not um specifically given p-values because these were considered nominal p-values.
- 26:03SPEAKER_01: This was not the primary input of the trial.
- 26:04SPEAKER_01: And so technically, this trial is a negative trial, but I would argue strongly it is not a negative trial.
- 26:12SPEAKER_01: So when you look at the 96 weeks, like I said, there's a very nice separation between drug and placebo.
- 26:17SPEAKER_01: Um, and then if you look at those who had um completed biopsies on both ends, you see that there is more of a separation even at 36 weeks, uh, but that really becomes even more pronounced at 96 weeks.
- 26:31SPEAKER_01: The other thing that is, I think, really important about this is that the nine, the non-invasive uh endpoints were also directionally aligned with this.
- 26:40SPEAKER_01: And so, this to me, although you can't take it in and of itself, um, I do think this gives us high confidence that when we look at this in the phase three trial, we will be um we will be happy.
- 26:53SPEAKER_01: I hope, I expect we'll see a statistically significant difference.
- 26:57SPEAKER_01: So, reviewing the safety parameters of fruxofermin in the serotic population, the adverse event profile was similar.
- 27:05SPEAKER_01: It was GI predominantly, and you can see here that the effruxofermin uh groups had higher uh rates of GI adverse events than placebo.
- 27:16SPEAKER_01: Specifically, the SAEs occurred in 25 and 18 percent of patients in the effruxofermin and placebo groups.
- 27:25SPEAKER_00: Thanks for that great summary.
- 27:26SPEAKER_00: We're gonna have one more audience response question, and um and then we will have a discussion about that.
- 27:33SPEAKER_00: But I think this study to me highlights uh two really important things.
- 27:38SPEAKER_00: Um first is as you say, um, when you extend the therapy to 96 weeks, you really start to see the differences emerge.
- 27:49SPEAKER_00: And the other is, you know, we are we're sort of wedded to this concept of intent-to-treat analysis, which of course was developed in the early days of cancer chemotherapy to address whether the toxicity would be something that would limit patients' ability to complete therapy.
- 28:09SPEAKER_00: But we apply it to now um hepatitis C trials where patients didn't show up for their HCV RNA, and we're applying it to NASH trials or MASH trials where patients have not had a follow-up biopsy.
- 28:24SPEAKER_00: And although it is the purest way to report it, to me, looking at completer analysis uh makes a lot more sense than simply assume every patient that did not have a biopsy is a treatment failure.
- 28:37SPEAKER_00: And I think this paper uh probably is the one paper that convinced me more than anything else that you should look at the supplementary material uh in the journal because uh you would not catch this if you did not read the supplementary material.
- 28:50SPEAKER_00: It's not anywhere in the manuscript or the abstract.
- 28:53SPEAKER_00: But uh, thanks for that great summary.
- 28:54SPEAKER_00: So here's our last audience response question.
- 28:57SPEAKER_00: Uh symmetry did not meet its week 36 primary endpoint, but showed a fibrosis improvement signal at week 96.
- 29:05SPEAKER_00: Which interpretation of this conclusion is most defensible?
- 29:10SPEAKER_00: Aphrexrexiformin is ineffective in compensated cirrhosis, B.
- 29:16SPEAKER_00: The trial is underpowered at both time points.
- 29:19SPEAKER_00: C.
- 29:20SPEAKER_00: The week 96 result establishes clinical benefit in compensated cirrhosis.
- 29:25SPEAKER_00: D.
- 29:25SPEAKER_00: The later week ninety-six signal supports continued study over longer timelines, but does not establish clinical benefit, and E.
- 29:33SPEAKER_00: I don't know.
- 29:54SPEAKER_00: The correct answer is D.
- 29:55SPEAKER_00: Uh Maru, what do you think about uh these choices?
- 29:58SPEAKER_00: Uh this would probably be hard to get right on a multiple choice test.
- 30:03SPEAKER_01: Yeah, no, I mean I think, I mean, unequivocally, the the answer is certainly gonna be D.
- 30:09SPEAKER_01: Um, I I do think that, I mean, again, and the reason why this is so exciting is because we had never shown in any disease state in a short period of time, short, I mean 96 weeks is decently short, um, to see reversal of cirrhosis histologically.
- 30:24SPEAKER_01: Now, an important point here is that we are talking about histological uh reversal.
- 30:30SPEAKER_01: Um, we are not talking about resolution of cirrhosis per se.
- 30:35SPEAKER_01: Um, so I do think it's important that this be studied in a larger trial, um, you know, so that we can, and then as follow-up to see if there is clinical benefit.
- 30:46SPEAKER_01: And by clinical benefit, we mean uh is there an improvement uh in how patients feel, function, or survive as a result of this treatment?
- 30:54SPEAKER_01: That is what has to be proven.
- 30:55SPEAKER_01: Uh, but I think this gives us high confidence.
- 30:58SPEAKER_01: It gives me high confidence.
- 31:00SPEAKER_00: Yeah, no, I think that's a very fair and reasonable uh take on these data.
- 31:05SPEAKER_00: So uh let's take a brief look at the ongoing phase three trials of FGF analogs and liver disease.
- 31:11SPEAKER_00: This is an active therapeutic area, a lot going on.
- 31:15SPEAKER_00: There's a fruxofermin, um, ephemusfermin, and pegasofermin all uh in a study window with um milestones expected to be reached uh anywhere from 2028 to 2032.
- 31:30SPEAKER_00: Um what are your thoughts about uh all of these trials, the synchrony trials, the zenith trials, the enlightened trials?
- 31:38SPEAKER_00: Um there's uh there's a lot going on, and we have a lot of uh of data that uh you know we'll we'll read out from these trials.
- 31:46SPEAKER_00: What do you hope these studies will show, Maru?
- 31:50SPEAKER_01: I mean, I hope that we're actually able to demonstrate that there's a reduction in liver-related outcomes.
- 31:55SPEAKER_01: That's really not been uh possible to be shown thus far.
- 32:00SPEAKER_01: So I really hope we're able to show a benefit, uh, you know, a reduction in in liver-related events ultimately in patients that are treated versus those that are not treated.
- 32:12SPEAKER_01: Um, I do think that, again, and this is just my my take on uh you know the importance of you know these incremental changes, the FDA does not have, as I mentioned, a reasonably likely surrogate approved for cirrhosis, um, which is the way things are right now.
- 32:29SPEAKER_01: But I do think that if these trials are able to show a reduction in multiple non-invasive tests in the same direction, um, and in some cases uh uh histology, I do think that may be, you know, hopefully it'll be enough even if outcome differences aren't met, because it's been exceedingly difficult.
- 32:51SPEAKER_01: And I do think the other thing that makes it a little bit more difficult in these ongoing trials currently is that the place, the the expected sort of outcome rates may be different because now we have, you know, more FGF, excuse me, more edge LP1 use in the background population.
- 33:10SPEAKER_01: We have um more uptake of of non-selective beta blockers being introduced with CSPH with the new Vivino uh consensus recommendations.
- 33:20SPEAKER_01: So I think it's gonna complicate and make demonstration of differences and outcomes gonna be more difficult.
- 33:26SPEAKER_01: That's my feeling on that.
- 33:28SPEAKER_00: Yeah, no, I think that's brilliant.
- 33:29SPEAKER_00: I think that's a great that's a great summary and kind of thinking into the future because uh, you know, having been involved intimately with uh the development of hepatitis C DAAs as a clinical investigator, I can tell you that um that it's taken years after these drugs were approved to really, from a population-based perspective, see reductions in HCC, uh, reduction in liver transplant outcomes, and so forth.
- 33:56SPEAKER_00: And you wonder, you know, what would have happened if we had waited another 10 years for those drugs to be approved.
- 34:03SPEAKER_00: The number of patients that would have developed end-stage liver disease need transplant, etc.
- 34:07SPEAKER_00: So, so I I I really like what you're saying about um adoption after rigorous evaluation, of course, yeah, uh of NITs uh in addition to clinical outcomes, and maybe uh being creative as long as we know that the safety and the toxicity, you know, is acceptable.
- 34:26SPEAKER_00: So with that, let me uh go ahead.
- 34:28SPEAKER_01: No, no, no.
- 34:29SPEAKER_01: I mean that's that's that I agree.
- 34:31SPEAKER_01: The only other comment are we gonna I the only other comment I want to say, just kind of looking at these uh programs, is so that the there is a sign, there is one difference um that that is worth noting, I think, especially with the Femis Fermin, um, in that there are two parallel trials.
- 34:48SPEAKER_01: And I I do think that the there's a little bit of a missed opportunity because one's a biopsy trial and the other one is uh is is is a bit it's a bit different.
- 34:58SPEAKER_01: So you're not going to be able to compare outcomes linking to to biopsy essentially, which may have been, I think, useful to do.
- 35:06SPEAKER_00: But yeah, I mean I think the more data we have that correlates uh biopsy with NITs, uh, the hopefully the faster we can sort of uh eliminate the biopsy and go to NITs.
- 35:20SPEAKER_00: Again, hep C is a great example.
- 35:22SPEAKER_00: Um, it was not a foregone conclusion that HCBRNA clearance was sufficient to meet regulatory approval.
- 35:29SPEAKER_00: It was actually quite quite fortunate that we were able to accomplish that.
- 35:33SPEAKER_00: So, with that, uh, I think it's a great way to go on to sort of talk about future perspectives.
- 35:38SPEAKER_00: I think we all agree that, especially in the patient with advanced fibrosis, we don't want to harm them.
- 35:44SPEAKER_00: So tolerability, side effect profile is going to be really critical.
- 35:48SPEAKER_00: And my impression uh, you know, is that the FGF-21 analogs so far appear to be pretty well tolerated even in patients with cirrhosis.
- 35:59SPEAKER_00: So I think that's encouraging, but we certainly want to learn as much as we can about side effects, especially as we start to treat patients with more advanced disease.
- 36:08SPEAKER_00: I think it's going to be really important to see, you know, where these therapies land in the landscape that is including more and more incretin-based therapies.
- 36:19SPEAKER_00: Uh, and what are we looking for in the phase three data?
- 36:23SPEAKER_00: So uh you alluded to the incretin-based um therapies, and certainly there we are uh eagerly waiting for dual agonists for glucagon, which potentially may have liver targeting effects.
- 36:38SPEAKER_00: We have uh we have triple agonists, uh retatrotide, for example, that has um very, very dramatic weight loss results.
- 36:48SPEAKER_00: And of course, we're keen to find out sarcopenia uh concerns being addressed and so forth.
- 36:55SPEAKER_00: Uh, where do you uh if you had a crystal ball, Maru, in five years, where do you think we would be?
- 37:00SPEAKER_00: Uh we'll still be enrolling in these trials.
- 37:03SPEAKER_01: I mean, yeah, I think we will.
- 37:05SPEAKER_01: I I think you know, the big question always is, you know, we have all these, we have a drug options now.
- 37:12SPEAKER_01: Um, you know, when can we sort of get rid of a placebo group?
- 37:16SPEAKER_01: Because we still will have to study drugs.
- 37:18SPEAKER_01: I mean, it it's, you know, we're gonna need several drugs to treat this very heterogeneous disease.
- 37:23SPEAKER_01: So I think until we have a fully approved drug, we will be using placebo.
- 37:28SPEAKER_01: Um, but I think we'll have to be uh creative.
- 37:31SPEAKER_01: Um, I do think though that there will be a background therapy or a backbone therapy uh in most of these uh patients.
- 37:38SPEAKER_01: Um GLP1s are likely to be uh important um players in that because they improve the metabolic dysfunction, which is a lot of the issue.
- 37:48SPEAKER_01: Um FGF-21 drugs are also, I think, potentially an interesting option for backbone, though they may be better suited for um sort of uh pulse therapy, but that hasn't been studied uh yet, and uh we we don't really know the answer to that.
- 38:04SPEAKER_01: And then um I presume that we will uh be managing people on a maintenance level with some sort of oral therapy, um, whether it's uh resmeterum or an oral GLP or other uh agents that are in development.
- 38:19SPEAKER_01: So it's hard to know, but um, in five years we won't have all those drugs approved, but we may have FGF-21s uh approved by then, hopefully we will.
- 38:27SPEAKER_00: Yeah, and for a complex disease that doesn't have one target, like clearing a virus, I think um it seems like when we have therapeutic options with multiple mechanisms of action, whether it's THR beta agonism, whether it's an increotin-based therapy, or whether it's an FGF-21 analog, it just seems common sense to try to combine them in a way that would achieve the greatest benefit.
- 38:51SPEAKER_00: So I think that's a great place to leave it.
- 38:54SPEAKER_00: Um to close, uh, we want to leave the audience with three practical, actionable, SMART goals, um, which I think is uh a very nice thing that CME Outfitters incorporates into uh the education uh materials.
- 39:09SPEAKER_00: And these are SMART goals you can take back to your practice setting and just a little checklist as to how this might influence your practice and what you learn today over the next 12 months.
- 39:21SPEAKER_00: Uh, review the FGF21 analog development pipeline at least quarterly.
- 39:26SPEAKER_00: Uh maybe keep your eyes and ears open when you get those automatic feeds from whatever GI society you belong to, or Internal Medicine Society or Obesity Society.
- 39:36SPEAKER_00: Um, noting agents in active F2, F3 match development, their phase and metabolic and antifibrotic rationale.
- 39:44SPEAKER_00: And I'm sure Maru and I, as both active clinical trialists, would very much want people to continue to refer patients for trials.
- 39:51SPEAKER_00: Um, and consider the FDA-approved therapies that are already in our toolbox.
- 39:57SPEAKER_00: And then within 60 days, critically appraise at least two phase 2B3 FGF21 analog trials in F2F3 MASH, comparing fibrosis improvement, MASH resolution, timing of assessment, and durability of response.
- 40:10SPEAKER_00: I think this will give us the ability to more critically evaluate this literature as it comes out, and the endpoints are variable and the assessments are timed differently, as Maru mentioned really nicely.
- 40:21SPEAKER_00: And then within 90 days, compare at least two FGF-21 studies and compensated cirrhosis with F2F3 trials on treatment duration, timing of assessments, and endpoint selection, and explain how these differences affect interpretation of antifibrotic effects.
- 40:37SPEAKER_00: So that uh very quickly uh time has flown.
- 40:40SPEAKER_00: This concludes our program today.
- 40:41SPEAKER_00: I'd like to thank my colleague, Dr.
- 40:42SPEAKER_00: Murray Ranella, for her invaluable insights, commentary, and her contributions to the field.
- 40:49SPEAKER_00: Uh and your uh nomenclature change is uh probably the most cited paper in uh all of liver disease, uh, maybe for all time.
- 40:59SPEAKER_00: So uh congrats to you on that.
- 41:01SPEAKER_00: I know that was not an easy task.
- 41:03SPEAKER_00: And thank you, our audience, for participating.
- 41:05SPEAKER_00: Just a quick reminder that to receive CMERC credit, you'll need to complete the post test and evaluation online.
- 41:11SPEAKER_00: Once completed, you'll be able to download and print your certificate right away.
- 41:16SPEAKER_00: Thank you so much for your attention.